A Study Using Human Abdominal Adipose Tissue Biopsies to Characterize the Role of Endocannabinoids in Adipocyte Differentiation (ECTADIF)
A Basic Study Using Human Abdominal Adipose Tissue Biopsies to Characterize the Role of Endocannabinoids in Adipocyte Differentiation
Abdominal obesity and type 2 diabetes are associated with hyperactivation of the endocannabinoid system. Several animal and human studies indicate that circulating endocannabinoid levels correlate with body fat mass. Thus, adipose tissue, which possesses the enzymatic machinery of the endocannabinoid system, may be the primary producer of plasma endocannabinoids.
Today, it is well established that stimulation of the endocannabinoid system, through the activation of cannabinoid receptor 1 (CB1R) located in the brain, leads to increased food intake and weight gain. Furthermore, peripheral CB1R present in adipose tissue are also directly involved in energy storage processes. Indeed, activation of the endocannabinoid system in adipose tissue is associated with stimulation of pathways leading to the uptake of carbohydrates and fatty acids, as well as their storage in the form of triglycerides.
Adipose tissue consists primarily of mature adipocytes, and activation of the endocannabinoid system appears to play a key role in increasing fat mass by promoting the hypertrophy of these adipocytes through the stimulation of lipogenesis. However, the vascular stromal fraction also contains stem cells capable of generating new adipocytes, and an autocrine action of endocannabinoids on progenitor cells could also contribute to its expansion by promoting hyperplasia.
That is why, in this project, the investigators aim to study the impact of endocannabinoids on the differentiation of stem cells from the stromal-vascular fraction into adipocytes. In particular, the investigators will seek to compare the impact of endocannabinoids on the differentiation capacity of stem cells derived from adipose tissue collected from patients with obesity, with or without diabetes, compared to controls.
These data, combined with those obtained in parallel in mice, could help determine whether adipose tissue (visceral and/or subcutaneous) is a priority target for the development of CB1R-blocking molecules (such as rimonabant) with exclusively peripheral action (which do not cross the blood-brain barrier to avoid psychiatric side effects) for the treatment of metabolic obesity and type 2 diabetes.
A tanulmány áttekintése
Állapot
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Bruno VERGES
- Telefonszám: +33 03.80.29.38.54
- E-mail: bruno.verges@chu-dijon.fr
Tanulmányi helyek
-
-
-
Dijon, Franciaország
- Toborzás
- CHU Dijon Bourgogne
-
Kapcsolatba lépni:
- Bruno VERGES
- Telefonszám: +33 03.80.29.38.54
- E-mail: bruno.verges@chu-dijon.fr
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
Control group :
- Men or postmenopausal women aged 18 to 80
- Individuals who have provided their free and informed written consent
- Individuals scheduled to undergo abdominal surgery
Non-diabetic obese individuals :
- Men or postmenopausal women aged 18 to 80
- BMI > 30 - Individuals who have provided written, free, and informed consent
- Scheduled to undergo abdominal surgery
Obese individuals with diabetes :
- Men or postmenopausal women aged 18 to 80 with type 2 diabetes not treated with insulin or a GLP-1 agonist
- BMI > 30
- Individuals who have provided written, free, and informed consent and are scheduled to undergo abdominal surgery
Exclusion Criteria :
Control group :
- Individuals not enrolled in or eligible for a social security program
- Individuals subject to legal guardianship (curatorship, guardianship)
- Individuals subject to judicial protective measures
- Pregnant women, women in labor, or breastfeeding women
- Adults who are legally incapacitated or unable to give consent
- Minors
- BMI > 30
- Diabetes
- Chronic inflammatory disease
- Cancer undergoing chemotherapy or having undergone chemotherapy within the past year
- Gastrointestinal cancer with recent weight loss and/or malnutrition
- Known metastatic cancers
- Cancers undergoing long-term hormonal therapy
- Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen testing, or testing for antibodies against the hepatitis C virus (HCV) with a positive HCV RNA test.
Non-diabetic obese individuals :
- Individuals not enrolled in or eligible for a social security program
- Individuals subject to legal guardianship (curatorship, guardianship)
- Individuals subject to judicial protective measures
- Pregnant women, women in labor, or breastfeeding women
- Adults who are legally incapacitated or unable to give consent
- Minors
- Diabetes
- Chronic inflammatory disease
- Cancer undergoing chemotherapy or having undergone chemotherapy within the past year
- Gastrointestinal cancer with recent weight loss and/or malnutrition
- Known metastatic cancers
- Cancers undergoing long-term hormonal therapy,
- Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or antibodies to hepatitis C virus (HCV) with a positive HCV RNA test.
Obese individuals with diabetes
- Individuals not enrolled in or not eligible for a social security program
- Individuals subject to legal guardianship (curatorship, guardianship)
- Individuals subject to judicial protective measures
- Pregnant women, women in labor, or breastfeeding women
- Adults who are legally incapacitated or unable to give consent
- Minors
- Diabetes
- Chronic inflammatory disease
- Cancer undergoing chemotherapy or having undergone chemotherapy within the past year
- Gastrointestinal cancer with recent weight loss and/or malnutrition
- Known metastatic cancers
- Cancers undergoing long-term hormonal therapy,
- Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or antibodies against hepatitis C virus (HCV) with a positive HCV RNA test.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Alapvető tudomány
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Egyéb: Ellenőrző csoport
|
Collection of small-volume adipose tissue samples (a few cubic centimeters) during a previously scheduled abdominal surgery.
|
|
Egyéb: Non-diabetic obese individuals
|
Collection of small-volume adipose tissue samples (a few cubic centimeters) during a previously scheduled abdominal surgery.
|
|
Egyéb: Obese individuals with diabetes
|
Collection of small-volume adipose tissue samples (a few cubic centimeters) during a previously scheduled abdominal surgery.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Monitoring the differentiation of stem cells from the stromal-vascular fraction into adipocytes
Időkeret: At baseline, biopsies of visceral and subcutaneous adipose tissue will be performed in the operating room during patients' visceral surgery. The samples will be promptly transferred to the INSERM laboratory for stem cell culture to assess adipocyte diffe
|
|
At baseline, biopsies of visceral and subcutaneous adipose tissue will be performed in the operating room during patients' visceral surgery. The samples will be promptly transferred to the INSERM laboratory for stem cell culture to assess adipocyte diffe
|
Együttműködők és nyomozók
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Egyéb vizsgálati azonosító számok
- VERGES 2025
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .